| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
Decanoic acid-d19 does not have a distinct pharmacological target separate from natural decanoic acid. Decanoic acid is a medium-chain saturated fatty acid that is metabolized in the body through beta-oxidation. It does not have a well-defined receptor target but is known to modulate various metabolic pathways. In the context of Decanoic acid-d19 as a stable isotope tracer, the compound is used primarily to study fatty acid metabolism and flux.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
As a stable isotope-labeled compound, Decanoic acid-d19 does not exhibit pharmacological activity distinct from that of natural decanoic acid. Decanoic acid itself is a medium-chain fatty acid that is rapidly oxidized in the liver and has been studied for its potential therapeutic effects in epilepsy and other neurological disorders. The deuterium labeling does not significantly alter the biological activity of decanoic acid, as the isotopic substitution does not affect the compound's chemical reactivity or metabolic properties. |
| ln Vivo |
In vivo, decanoic acid is a medium-chain fatty acid that is rapidly absorbed and metabolized. It is transported to the liver via the portal vein, where it undergoes beta-oxidation to produce acetyl-CoA and ketone bodies. Decanoic acid has been studied for its potential therapeutic effects in epilepsy, where it may exert anticonvulsant effects through modulation of mitochondrial function and energy metabolism. Decanoic acid-d19 is used as a tracer to study these metabolic processes.
|
| Enzyme Assay |
In vitro assays for Decanoic acid-d19 typically involve the use of the compound as an internal standard in analytical methods such as GC-MS or LC-MS for the quantification of decanoic acid in biological samples. The compound is added to samples prior to extraction and analysis, and the ratio of the labeled to unlabeled compound is used to calculate the concentration of decanoic acid.
|
| Cell Assay |
In vitro cell-based assays using Decanoic acid-d19 typically involve the incubation of cultured cells with the labeled compound to study fatty acid metabolism. Cells are cultured in media containing the labeled decanoic acid, and after a designated incubation period, metabolites are extracted and analyzed by mass spectrometry to determine the incorporation of the deuterium label into various metabolites. This approach is used to study beta-oxidation and lipid metabolism.
|
| Animal Protocol |
In vivo animal studies with Decanoic acid-d19 typically involve the administration of the labeled compound to rodents or other model organisms via oral gavage or intravenous injection. Following administration, blood, tissues, and urine are collected at various time points, and the samples are analyzed by mass spectrometry to trace the metabolic fate of the labeled decanoic acid. This approach is used to study whole-body fatty acid metabolism.
|
| ADME/Pharmacokinetics |
Decanoic acid-d19 is not a drug and does not have pharmacokinetic properties distinct from those of natural decanoic acid. Decanoic acid is a medium-chain fatty acid that is rapidly absorbed from the gastrointestinal tract and transported to the liver via the portal vein. It is metabolized through beta-oxidation to produce acetyl-CoA and ketone bodies. The pharmacokinetic behavior of the deuterated compound is identical to that of unlabeled decanoic acid.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are publicly available for Decanoic acid-d19. As a stable isotope-labeled form of the naturally occurring fatty acid decanoic acid, the compound is expected to have a low toxicity profile similar to that of natural decanoic acid. Decanoic acid is generally recognized as safe and is well-tolerated at physiological concentrations. The deuterium labeling does not introduce any additional toxicity.
|
| References | |
| Additional Infomation |
Decanoic acid-d19 is the perdeuterated isotopologue of the medium-chain saturated fatty acid decanoic acid, where all 19 aliphatic hydrogen atoms are replaced with deuterium. It is used as an internal standard for the quantification of decanoic acid by GC-MS or LC-MS and as a stable isotope-labeled tracer in metabolic studies. The compound is not a drug and has no approved clinical indications. It is strictly for research purposes. The compound has the CAS number 88170-22-3.
|
| Molecular Formula |
C10HD19O2
|
|---|---|
| Molecular Weight |
191.38
|
| Exact Mass |
191.266
|
| CAS # |
88170-22-3
|
| Related CAS # |
Decanoic acid;334-48-5;Decanoic acid-d3;102611-15-4
|
| PubChem CID |
16213405
|
| Appearance |
White to light yellow solid-liquid Mixture
|
| Density |
0.991 g/mL at 25ºC
|
| Boiling Point |
268-270ºC(lit.)
|
| Melting Point |
30-32ºC(lit.)
|
| LogP |
3.211
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
12
|
| Complexity |
110
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C([2H])([2H])(C([2H])([2H])C([2H])([2H])C(=O)O)C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H]
|
| InChi Key |
GHVNFZFCNZKVNT-KIJKOTCYSA-N
|
| InChi Code |
InChI=1S/C10H20O2/c1-2-3-4-5-6-7-8-9-10(11)12/h2-9H2,1H3,(H,11,12)/i1D3,2D2,3D2,4D2,5D2,6D2,7D2,8D2,9D2
|
| Chemical Name |
2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-nonadecadeuteriodecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.2252 mL | 26.1260 mL | 52.2521 mL | |
| 5 mM | 1.0450 mL | 5.2252 mL | 10.4504 mL | |
| 10 mM | 0.5225 mL | 2.6126 mL | 5.2252 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
